Brenipatide (LY3537031) treatment for adults with IBS‑D
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D
Run by Eli Lilly and Company · NCT07545759 · Data updated 2026-11-12
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 531 (estimated) |
| Sponsor | Eli Lilly and Company Industry-sponsored |
| Locations | 89 sites (Mesa, Arizona and 88 other locations) |
| Status | Recruiting |
| Started | May 6, 2026 |
| Main results expected | September 2027 |
| Study ends | November 2027 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT07545759 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who meet Rome IV criteria for IBS‑D with frequent loose stools (BSFS types 6–7 on a substantial portion of bowel movements), an average worst abdominal pain score ≥3 on a 0–10 scale during screening, and no major recent diet changes are the intended participants.
✕Probably not a fit
People with constipation‑predominant, mixed, or unclassified IBS, those with inflammatory or immune-mediated gastrointestinal disorders, or those with known clinically significant gastric emptying abnormalities are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 study gives adults with IBS‑D subcutaneous injections of brenipatide (LY3537031) or placebo over an approximately 35‑week period to characterize safety, tolerability, side effects, and preliminary symptom effects. Participants complete a daily eDiary during screening and treatment to confirm Rome IV IBS‑D criteria and to track abdominal pain and stool form. The trial compares patient-reported outcomes between the brenipatide and placebo groups and excludes people with other IBS subtypes or inflammatory/immune‑mediated GI disorders. Dosing and follow-up visits occur at clinical sites in the United States.
Why it matters
Potential benefit: If successful, brenipatide could reduce abdominal pain and diarrhea and improve daily functioning for people with IBS‑D.
How similar studies have gone: Some other peptide- or receptor-targeting drugs for IBS‑D have shown symptom benefit in prior trials, but brenipatide (LY3537031) is a novel agent and its efficacy has not yet been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet Rome IV criteria for IBS-D, which includes having greater than 25% of bowel movements with Bristol Stool Form Scale (BSFS) Types 6 or 7 and \<25% of bowel movements with BSFS Types 1 or 2 * Based on the daily eDiary collection during the screening period: * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization * Have at least 4 days per week with a maximum BSFS ≥5 AND with at least 2 days of the 4 days per week with a maximum BSFS ≥6 during the 14 consecutive days prior to randomization * Have had no major changes in diet in the 4 weeks prior to screening Exclusion Criteria: * Have a diagnosis of IBS with a subtype of constipation, mixed IBS, or unclassified IBS by the Rome IV criteria * Have a history of inflammatory or immune-mediated gastrointestinal disorders * Have a known clinically significant gastric emptying abnormality
Where it's running
-
Del Sol Research Management - Mesa
Mesa, Arizona, United States Recruiting -
Smart Cures Clinical Research
Anaheim, California, United States Recruiting -
Om Research LLC
Lancaster, California, United States Recruiting -
United Medical Doctors - Los Alamitos
Los Alamitos, California, United States Recruiting -
Encore Medical Research
Hollywood, Florida, United States Recruiting -
Clinical Research of Osceola
Kissimmee, Florida, United States Recruiting
Show 44 more locations
-
Springfield Clinic - First
Springfield, Illinois, United States Recruiting -
Gastroenterology Health Partners
New Albany, Indiana, United States Recruiting -
Gastroenterology Health Partners
Louisville, Kentucky, United States Recruiting -
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
Wyoming, Michigan, United States Recruiting -
Ohio Gastroenterology
Columbus, Ohio, United States Recruiting -
University Gastroenterology
Providence, Rhode Island, United States Recruiting -
Biopharma Informatic, LLC
McAllen, Texas, United States Recruiting -
Southern Star Research Institute
San Antonio, Texas, United States Recruiting -
AZ Maria Middelares
Ghent, Belgium Recruiting -
AZ Sint-Lucas
Ghent, Belgium Recruiting -
UZ Leuven
Leuven, Belgium Recruiting -
Clinical Chc Montlégia
Liège, Belgium Recruiting -
AZ Delta vzw
Roeselare, Belgium Recruiting -
Bluewater Clinical Research Group Inc.
Sarnia, Canada Recruiting -
Scarborough Center for Inflammatory Bowel Disease
Scarborough, Canada Recruiting -
ClinSurge Research - LMC Scarborough / Malvern Medical Centre
Scarborough, Canada Recruiting -
Stouffville Medical Research Institute Inc.
Stouffville, Canada Recruiting -
Canadian Phase Onward
Toronto, Canada Recruiting -
Binzhou Medical University Hospital
Binzhou, China Recruiting -
Sichuan Provincial People's Hospital
Chengdu, China Recruiting -
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China Recruiting -
Zhejiang Hospital of Traditioal Chinese Medicine
Hangzhou, China Recruiting -
The Second Affiliated Hospital of University of South China
Hengyang, China Recruiting -
Huizhou Central People's Hospital
Huizhou, China Recruiting -
Huzhou Central Hospital
Huzhou, China Recruiting -
Meihekou Central Hospital
Meihekou, China Recruiting -
Quzhou People's Hospital
Quzhou, China Recruiting -
Taian City Central Hospital
Taian, China Recruiting -
Xianning Central Hospital
Xianning, China Recruiting -
Yichun People's Hospital
Yichun, China Recruiting -
FutureMeds GmbH
Berlin, Germany Recruiting -
Studienzentrum MVZ Dachau
Dachau, Germany Recruiting -
Pratia - Hamburg
Hamburg, Germany Recruiting -
Klinische Forschung Karlsruhe
Karlsruhe, Germany Recruiting -
AmBeNet GmbH
Leipzig, Germany Recruiting -
FutureMeds Offenbach
Offenbach, Germany Recruiting -
Tokyo-Eki Center-building Clinic
Chūōku, Japan Recruiting -
Sai Gastroenterology/Proctology Clinic
Fujiidera, Japan Recruiting -
Tokai University Hospital
Isehara, Japan Recruiting -
Aoyama Internal Medicine Clinic
Kobe, Japan Recruiting -
Aono Clinic
Kobe, Japan Recruiting -
Hattori Clinic - Kumamoto
Kumamoto, Japan Recruiting -
Sapporo Odori Endoscope Clinic
Sapporo, Japan Recruiting -
Nishi-Shinjuku Kisaragi Clinic
Shinjuku-Ku, Japan Recruiting
+39 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Email: LillyTrials@Lilly.com
- Phone: 1-317-615-4559
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fecal microbiota transplantation for treating irritable bowel syndrome
This study is testing if using stool from a healthy donor can help people with irritable bowel syndrome feel better by restoring a healthy balance of gut bacteria.
-
Gut health follow-along with Peachbiotic in adults
This single-arm study tests whether Peachbiotic taken daily for 12 weeks helps adults with gut symptoms feel better.
-
Impact of a climate-resilient WASH package in Karamoja schools
This study tests a climate-resilient water, sanitation and hygiene package in severely water-insecure primary schools in Karamoja to see if it reduces diarrhea and respiratory infections and improves attendance, especially among girls.
-
Do home water filters improve health for people with private wells in rural Central Appalachia
This study tests whether providing point-of-use water filters to households using well or spring water in rural Central Appalachia can reduce acute gastrointestinal illness.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Balanced IV Fluids for Kids with Acute Gastroenteritis
This study compares balanced crystalloids versus normal saline for IV hydration in young children with acute gastroenteritis to see if it improves acid–base status and clinical outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.